BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Farmers Insurance
Harvard Business School

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,905,082

« Back to Dashboard

Which drugs does patent 5,905,082 protect, and when does it expire?

Patent 5,905,082 protects EPIVIR, COMBIVIR, EPIVIR-HBV, EPZICOM, TRIUMEQ, and TRIZIVIR, and is included in seven NDAs. There have been zero Paragraph IV challenges on Triumeq, Trizivir, Epivir-HBV, Epivir, Epzicom, and Combivir.

Protection for EPIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty patent family members in twenty-eight countries.

Summary for Patent: 5,905,082

Title: Crystalline oxathiolane derivatives
Abstract:(-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
Inventor(s): Roberts; Tony Gordon (Ware, GB), Evans; Paul (Ware, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Application Number:07/892,029
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Viiv HlthcareEPIVIRlamivudineSOLUTION;ORAL020596-001Nov 17, 1995AARXYesYes► Subscribe► Subscribe► Subscribe
Viiv HlthcareCOMBIVIRlamivudine; zidovudineTABLET;ORAL020857-001Sep 26, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
Viiv HlthcareEPIVIRlamivudineTABLET;ORAL020564-001Nov 17, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
Viiv HlthcareEPIVIRlamivudineTABLET;ORAL020564-003Jun 24, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe
GlaxosmithklineEPIVIR-HBVlamivudineTABLET;ORAL021003-001Dec 8, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Viiv HlthcareEPZICOMabacavir sulfate; lamivudineTABLET;ORAL021652-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
Viiv HlthcareTRIUMEQabacavir sulfate; dolutegravir sodium; lamivudineTABLET;ORAL205551-001Aug 22, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Viiv HlthcareTRIZIVIRabacavir sulfate; lamivudine; zidovudineTABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,905,082

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom91 11902Jun 03, 1991

International Patent Family for Patent: 5,905,082

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ireland20020782► Subscribe
Ireland921780► Subscribe
Hong Kong1009599► Subscribe
United Kingdom9111902► Subscribe
Spain2171158► Subscribe
Canada2311988► Subscribe
Canada2070230► Subscribe
Czech Republic9302612► Subscribe
Czech Republic284513► Subscribe
Germany69232387► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
US Army
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: